AI in Healthcare

Bengaluru's Tata Elxsi Has Launched ViTel — AI-Powered Material Intelligence for Medical Device Manufacturers Built for the Post-Tariff, Post-BIOSECURE Supply Chain Reality

By Mustafa Shariff, Editor in Chief · June 02,2026 · 2 min read

Summary

• Tata Elxsi's ViTel: Why Medical Device Manufacturers Now Need AI Material Intelligence
• Tata Elxsi has launched ViTel, an AI-powered material intelligence solution for medical device manufacturers. Here is the full story of what it solves and why the timing is critical.

"ViTel brings material intelligence directly into the product and compliance workflows that matter most — helping our customers make faster, more confident decisions across sourcing, engineering, quality, and regulatory readiness."

Tata Elxsi — the Bengaluru-headquartered engineering services and technology solutions company with one of India's most respected healthcare and life sciences practices — has announced the launch of ViTel: a material intelligence solution for medical device manufacturers, developed in collaboration with Viridium AI, a material intelligence platform company. ViTel was formally introduced at DeviceTalks Boston 2026, positioning it directly in front of the international medical device industry's decision-makers.

The problem ViTel is designed to solve is specific and increasingly urgent. Medical device manufacturers operate in an environment where material decisions have become strategically critical — affecting product margins through raw material cost volatility, supply chain resilience through country-of-origin dependencies, product velocity through regulatory approval timelines tied to material specifications, and market access through country-specific material restriction requirements. Yet the knowledge required to make informed material decisions is typically fragmented: scattered across Bills of Materials, supplier documentation, ERP and PLM systems, regulatory filings, and the tacit knowledge of experienced engineers who may be unavailable or may not have been asked the right questions.

What ViTel Does

ViTel creates what Sreevatsa Sahasranaman, Senior Vice President and Head of Healthcare and Life Sciences at Tata Elxsi, describes as a reusable material intelligence layer across the enterprise. The system ingests and integrates materials data from across a device manufacturer's enterprise — BOMs, supplier documents, procurement records, regulatory submissions, ERP systems — and provides structured analytical capabilities on top of that integrated data.

Specifically: identifying material and supplier dependencies that create concentration risk; assessing country-of-origin and sourcing exposure for critical materials; evaluating alternative materials and suppliers against cost, quality, regulatory acceptability, and availability criteria; and understanding where specific product or material decisions create regulatory compliance risk in target markets. The system makes these assessments visible and actionable within the product and compliance workflows where material decisions are actually made — rather than requiring separate analytical exercises that disrupt engineering and regulatory timelines.

Why This Matters Now — The Three Converging Forces

ViTel's launch timing is not coincidental. Three converging forces have made material intelligence a strategic necessity for medical device manufacturers in 2026 in a way it was not five years ago.

The BIOSECURE Act policy risk — covered in BHC Media's May 26 edition — has medical device manufacturers specifically examining their supply chain exposure to Chinese component manufacturers, raw material suppliers, and electronic assembly contractors. For medical devices, which typically involve electronic components sourced from Asian supply chains, the BIOSECURE Act's potential restriction of specific Chinese manufacturers creates material-level supply chain risk that requires exactly the kind of country-of-origin mapping and alternative supplier assessment that ViTel provides.

The US-China tariff regime — which has imposed significant additional costs on Chinese-manufactured goods imported into the United States — has accelerated the supply chain diversification exercise that medical device manufacturers had been conducting slowly for years. Understanding which materials and components in a device's BOM carry Chinese-origin tariff exposure, and evaluating alternative sourcing options, is a material intelligence problem.

Operation Epic Fury and its disruption of Middle East shipping routes — covered in BHC Media's May 26 edition — has added a geographic dimension to supply chain risk assessment: understanding not just country-of-origin but transit route dependency for critical materials.

The Bengaluru and India Connection

Tata Elxsi's healthcare and life sciences practice is headquartered in Bengaluru — part of the city's substantial engineering services and technology sector that serves global healthcare clients from an India base. The ViTel launch is consistent with a broader pattern of Bengaluru-based technology companies building healthcare-specific AI capabilities that address global market needs: Qure.ai in medical imaging, Tricog in cardiac diagnostics, DeepTek in radiology AI, and now Tata Elxsi in medical device material intelligence.

BHC Perspective

At Bengaluru Health Community, Tata Elxsi's ViTel is a story about Bengaluru's engineering services sector moving up the value chain in healthcare technology — from implementation services to AI-powered product intelligence. For BHC founders building in MedTech, supply chain technology, or regulatory compliance tools — ViTel models the kind of AI application that creates durable enterprise value in the healthcare manufacturing sector.

Frequently Asked Questions

Q: What is ViTel?
A: Tata Elxsi's AI-powered material intelligence solution for medical device manufacturers, developed with Viridium AI. It creates a unified material intelligence layer across enterprise data sources to identify supply chain dependencies, assess country-of-origin exposure, evaluate alternatives, and track compliance risks.

Q: Why is material intelligence a medical device priority now?
A: Three converging forces: BIOSECURE Act risk targeting Chinese pharmaceutical manufacturers with supply chain spillover to medical devices; US-China tariff exposure requiring Chinese-origin cost assessment; and Operation Epic Fury-driven shipping disruption highlighting transit route dependencies.

Q: Who built ViTel and where?
A: Tata Elxsi (Bengaluru headquarters, healthcare and life sciences practice) in collaboration with Viridium AI. Launched at DeviceTalks Boston 2026.